Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT02984982
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 206 participants
- Sponsor
- Registry
-
NCT02984982
-
- Other papers using this trial's data
- Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02984982. Randomized; no masking; primary purpose treatment. Start 2016-11-15 (actual); primary completion 2018-07-27 (actual). Results posted on 2019-09-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
- Acronym
- ODYSSEY J-IVUS
- Condition
- Hypercholesterolemia
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Alirocumab SAR236553
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Fenofibrate
- Intervention (Drug)
- Bezafibrate
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Antiplatelets
- Intervention (Drug)
- Anticoagulants
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02984982- Content hash
0d15326036b6fdfca938899cdf4e195238861da606325012ee5ab33e477ba067